Iran Tightens Grip on Strait of Hormuz as Oil Prices Surge 
Trump Administration Proposes New Rule to Limit Joint Employer Liability 
U.S. Allows Iran Players in 2026 World Cup but Bars IRGC-Linked Individuals 
Navy Secretary John Phelan Fired Amid Pentagon Leadership Shakeup and Shipbuilding Concerns 
New Zealand Labour Backs India Free Trade Deal, Boosting Chances of Parliamentary Approval 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
U.S. Raises Security Concerns Over Chinese Infrastructure in Argentina Amid Growing Regional Ties 
Florida Governor Ron DeSantis Signs Law Restricting DEI Programs and Climate Initiatives 
Israeli Airstrike in Northern Gaza Kills Five Palestinians Amid Fragile Ceasefire 
Mexico Senate Seeks Answers on Deadly Chihuahua Crash Involving U.S. and Mexican Officials 
Taiwan Coast Guard Conducts Rare Drill on Disputed South China Sea Island 
Lebanon-Israel Ceasefire Extended as U.S. Pushes for Peace Talks 
Trump Administration Considers Expanding Refugee Program for White South Africans 
U.S. Intercepts Iranian Oil Tankers in Asian Waters Amid Rising Global Energy Crisis 
U.S. Criticizes Airspace Denials to Taiwan President as China Influence Grows 
Trump Plans to Invite Putin to G20 Summit in Miami, Report Says 
US and EU Strengthen Critical Minerals Partnership to Reduce China Dependence 
U.S. President Donald Trump recently sparked renewed discussion around cannabidiol regulation after calling on Congress to modernize existing laws to allow broader access to “full-spectrum” CBD products. In a post shared on Truth Social, Trump emphasized the need for updated legislation that ensures Americans can benefit from the full range of hemp-derived compounds, not just isolated CBD.
Full-spectrum CBD refers to products that contain a variety of naturally occurring cannabinoids, terpenes, and other compounds found in the cannabis plant, including trace amounts of THC within federally legal limits. Advocates argue that these compounds work together in what is known as the “entourage effect,” potentially enhancing the therapeutic benefits of CBD for issues such as anxiety, chronic pain, inflammation, and sleep disorders.
Trump’s statement highlights a growing debate in the U.S. CBD market, where current regulations remain fragmented and often unclear. While the 2018 Farm Bill legalized hemp-derived CBD at the federal level, restrictions and inconsistencies continue to limit consumer access to certain formulations, particularly full-spectrum products. Industry leaders and stakeholders have long pushed for clearer guidelines to support innovation, ensure product safety, and expand market opportunities.
The call for reform also reflects increasing consumer demand for natural wellness solutions. The global CBD market has seen rapid growth, driven by rising awareness of its potential health benefits and shifting public perception of cannabis-related products. However, regulatory uncertainty has slowed progress in areas such as product labeling, quality control, and interstate commerce.
By urging Congress to revisit CBD legislation, Trump has added momentum to ongoing discussions about cannabis policy reform in the United States. Supporters believe that updated laws could strengthen the domestic hemp industry, create jobs, and provide consumers with safer, more effective CBD options. As lawmakers consider potential changes, the future of full-spectrum CBD products in the U.S. remains a closely watched issue for both businesses and consumers alike.
